Markers of bone turnover for the management of patients with bone metastases from prostate cancer

Abstract

Although increased bone formation is a prominent feature of patients with osteosclerotic metastases from prostate cancer, there is also some evidence for increased bone resorption. The aim of this study was to compare the clinical utility of new bone resorption markers to that of bone formation in patients with bone metastases from prostate cancer before and after bisphosphonate treatment. Thirty-nine patients with prostate cancer and bone metastasis, nine patients with prostate cancer without bone metastases, nine patients with benign prostatic hyperplasia and 355 healthy age-matched men were included. Urinary non-isomerized (alpha CTX) and beta isomerized (beta CTX) type I collagen C-telopeptides (CTX) and a new assay for serum CTX were used to assess bone resorption. Bone formation was determined by serum osteocalcin, serum total (T-ALP) and bone (BAP) alkaline phosphatase and serum type I collagen C-terminal propeptide (PICP). Fourteen patients with bone metastases were also evaluated 15 days after a single injection of the bisphosphonate pamidronate (120 mg). Levels of all bone formation and bone resorption markers were significantly (P < 0.006-0.0001) higher in patients with prostate cancer and bone metastasis than in patients with benign prostatic hyperplasia, patients with prostate cancer without bone metastases and healthy controls. In patients with bone metastases the median was increased by 67% for serum osteocalcin, 128% for T-ALP, 138% for BAP, 79% for PICP, 220% for urinary alpha CTX, 149% for urinary beta CTX and 214% for serum CTX. After bisphosphonate treatment all three resorption markers significantly decreased by an average of 65% (P = 0.001), 71% (P = 0.0010) and 61% (P = 0.0015) for urinary alpha CTX, urinary beta CTX and serum CTX, respectively, whereas no significant change was observed for any bone formation markers. Patients with prostate cancer and bone metastases exhibit a marked increase in bone resorption, which decreases within a few days of treatment with pamidronate. These findings suggest that these new resorption markers may be useful for the management of these patients.

References 52

1. 1.

   Adami S. Bisphosphonates in prostate carcinoma. Cancer. 1997;80(8 Suppl):1674-1679.

   Not in our library10.1002/(sici)1097-0142(19971015)80:8+<1674::aid-cncr18>3.3.co;2-d

2. 2.

   Adami S., Salvagno G., Guarrera G., Bianchi G., Dorizzi R., Rosini S., Mobilio G., Lo Cascio V. Dichloromethylene-diphosphonate in patients with prostatic carcinoma metastatic to the skeleton. J Urol. 1985;134(6):1152-1154.

   Not in our library10.1016/s0022-5347(17)47663-4

3. 3.

   Akimoto S., Furuya Y., Akakura K., Ito H. Comparison of markers of bone formation and resorption in prostate cancer patients to predict bone metastasis. Endocr J. 1998;45(1):97-104.

   Not in our library10.1507/endocrj.45.97

4. 4.

   Berenson J. R., Lichtenstein A., Porter L., Dimopoulos M. A., Bordoni R., George S., Lipton A., Keller A., Ballester O., Kovacs M. J. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group. N Engl J Med. 1996;334(8):488-493.

   Not in our library10.1056/nejm199602223340802

5. 5.

   Berruti A., Piovesan A., Torta M., Raucci C. A., Gorzegno G., Paccotti P., Dogliotti L., Angeli A. Biochemical evaluation of bone turnover in cancer patients with bone metastases: relationship with radiograph appearances and disease extension. Br J Cancer. 1996;73(12):1581-1587.

   Not in our library10.1038/bjc.1996.298

6. 6.

   Blom E., Ali M. M., Mortensen B., Huseby N. E. Elimination of alkaline phosphatases from circulation by the galactose receptor. Different isoforms are cleared at various rates. Clin Chim Acta. 1998;270(2):125-137.

   Not in our library10.1016/s0009-8981(97)00217-9

7. 7.

   Body J. J., Coleman R. E., Piccart M. Use of bisphosphonates in cancer patients. Cancer Treat Rev. 1996;22(4):265-287.

   Not in our library10.1016/s0305-7372(96)90020-1

8. 8.

   Bonde M., Fledelius C., Qvist P., Christiansen C. Coated-tube radioimmunoassay for C-telopeptides of type I collagen to assess bone resorption. Clin Chem. 1996;42(10):1639-1644.

   Not in our library

9. 9.

   Bonde M., Garnero P., Fledelius C., Qvist P., Delmas P. D., Christiansen C. Measurement of bone degradation products in serum using antibodies reactive with an isomerized form of an 8 amino acid sequence of the C-telopeptide of type I collagen. J Bone Miner Res. 1997;12(7):1028-1034.

   Not in our library10.1359/jbmr.1997.12.7.1028

10. 10.

    Bonde M., Qvist P., Fledelius C., Riis B. J., Christiansen C. Immunoassay for quantifying type I collagen degradation products in urine evaluated. Clin Chem. 1994;40(11 Pt 1):2022-2025.

    Not in our library

11. 11.

    Carey P. O., Lippert M. C. Treatment of painful prostatic bone metastases with oral etidronate disodium. Urology. 1988;32(5):403-407.

    Not in our library10.1016/0090-4295(88)90410-4

12. 12.

    Clarke N. W., McClure J., George N. J. Disodium pamidronate identifies differential osteoclastic bone resorption in metastatic prostate cancer. Br J Urol. 1992;69(1):64-70.

    Not in our library10.1111/j.1464-410x.1992.tb15461.x

13. 13.

    Clarke N. W., McClure J., George N. J. Morphometric evidence for bone resorption and replacement in prostate cancer. Br J Urol. 1991;68(1):74-80.

    Not in our library10.1111/j.1464-410x.1991.tb15260.x

14. 14.

    Coleman R. E. Monitoring of bone metastases. Eur J Cancer. 1998;34(2):252-259.

    Not in our library10.1016/s0959-8049(97)10134-4

15. 15.

    Delmas P. D., Demiaux B., Malaval L., Chapuy M. C., Meunier P. J. Serum bone GLA-protein is not a sensitive marker of bone turnover in Paget's disease of bone. Calcif Tissue Int. 1986;38(1):60-61.

    Not in our library10.1007/bf02556596

16. 16.

    Elomaa I., Kylmälä T., Tammela T., Viitanen J., Ottelin J., Ruutu M., Jauhiainen K., Ala-Opas M., Roos L., Seppänen J. Effect of oral clodronate on bone pain. A controlled study in patients with metastic prostatic cancer. Int Urol Nephrol. 1992;24(2):159-166.

    Not in our library10.1007/bf02549644

17. 17.

    Engler H., Koeberle D., Thuerlimann B., Senn H. J., Riesen W. F. Diagnostic and prognostic value of biochemical markers in malignant bone disease: a prospective study on the effect of bisphosphonate on pain intensity and progression of malignant bone disease. Clin Chem Lab Med. 1998;36(11):879-885.

    Not in our library10.1515/cclm.1998.154

18. 18.

    Fledelius C., Johnsen A. H., Cloos P. A., Bonde M., Qvist P. Characterization of urinary degradation products derived from type I collagen. Identification of a beta-isomerized Asp-Gly sequence within the C-terminal telopeptide (alpha1) region. J Biol Chem. 1997;272(15):9755-9763.

    Not in our library10.1074/jbc.272.15.9755

19. 19.

    Garnero P., Fledelius C., Gineyts E., Serre C. M., Vignot E., Delmas P. D. Decreased beta-isomerization of the C-terminal telopeptide of type I collagen alpha 1 chain in Paget's disease of bone. J Bone Miner Res. 1997;12(9):1407-1415.

    Not in our library10.1359/jbmr.1997.12.9.1407

20. 20.

    Garnero P., Gineyts E., Schaffer A. V., Seaman J., Delmas P. D. Measurement of urinary excretion of nonisomerized and beta-isomerized forms of type I collagen breakdown products to monitor the effects of the bisphosphonate zoledronate in Paget's disease. Arthritis Rheum. 1998;41(2):354-360.

    Not in our library10.1002/1529-0131(199802)41:2<354::aid-art20>3.0.co;2-5

21. 21.

    Garnero P., Grimaux M., Demiaux B., Preaudat C., Seguin P., Delmas P. D. Measurement of serum osteocalcin with a human-specific two-site immunoradiometric assay. J Bone Miner Res. 1992;7(12):1389-1398.

    Not in our library10.1002/jbmr.5650071206

22. 22.

    Garnero P., Shih W. J., Gineyts E., Karpf D. B., Delmas P. D. Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment. J Clin Endocrinol Metab. 1994;79(6):1693-1700.

    Not in our library10.1210/jcem.79.6.7989477

23. 23.

    Gomez B., Ardakani S., Ju J., Jenkins D., Cerelli M. J., Daniloff G. Y., Kung V. T. Monoclonal antibody assay for measuring bone-specific alkaline phosphatase activity in serum. Clin Chem. 1995;41(11):1560-1566.

    Not in our library

24. 24.

    Hannon R., Blumsohn A., Naylor K., Eastell R. Response of biochemical markers of bone turnover to hormone replacement therapy: impact of biological variability. J Bone Miner Res. 1998;13(7):1124-1133.

    Not in our library10.1359/jbmr.1998.13.7.1124

25. 25.

    Hassager C., Jensen L. T., Pødenphant J., Thomsen K., Christiansen C. The carboxy-terminal pyridinoline cross-linked telopeptide of type I collagen in serum as a marker of bone resorption: the effect of nandrolone decanoate and hormone replacement therapy. Calcif Tissue Int. 1994;54(1):30-33.

    Not in our library10.1007/bf00316286

26. 26.

    Hortobagyi G. N., Theriault R. L., Porter L., Blayney D., Lipton A., Sinoff C., Wheeler H., Simeone J. F., Seaman J., Knight R. D. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group. N Engl J Med. 1996;335(24):1785-1791.

    Not in our library10.1056/nejm199612123352401

27. 27.

    Ikeda I., Miura T., Kondo I. Pyridinium cross-links as urinary markers of bone metastases in patients with prostate cancer. Br J Urol. 1996;77(1):102-106.

    Not in our library10.1046/j.1464-410x.1996.82817.x

28. 28.

    Koizumi M., Maeda H., Yoshimura K., Yamauchi T., Kawai T., Ogata E. Dissociation of bone formation markers in bone metastasis of prostate cancer. Br J Cancer. 1997;75(11):1601-1604.

    Not in our library10.1038/bjc.1997.273

29. 29.

    Kylmälä T., Tammela T. L., Risteli L., Risteli J., Kontturi M., Elomaa I. Type I collagen degradation product (ICTP) gives information about the nature of bone metastases and has prognostic value in prostate cancer. Br J Cancer. 1995;71(5):1061-1064.

    Not in our library10.1038/bjc.1995.204

30. 30.

    Kylmälä T., Tammela T., Risteli L., Risteli J., Taube T., Elomaa I. Evaluation of the effect of oral clodronate on skeletal metastases with type 1 collagen metabolites. A controlled trial of the Finnish Prostate Cancer Group. Eur J Cancer. 1993;29A(6):821-825.

    Not in our library10.1016/s0959-8049(05)80417-4

31. 31.

    Lorente J. A., Morote J., Raventos C., Encabo G., Valenzuela H. Clinical efficacy of bone alkaline phosphatase and prostate specific antigen in the diagnosis of bone metastasis in prostate cancer. J Urol. 1996;155(4):1348-1351.

    Not in our library

32. 32.

    Maeda H., Koizumi M., Yoshimura K., Yamauchi T., Kawai T., Ogata E. Correlation between bone metabolic markers and bone scan in prostatic cancer. J Urol. 1997;157(2):539-543.

    Not in our library

33. 33.

    Miyamoto K. K., McSherry S. A., Robins S. P., Besterman J. M., Mohler J. L. Collagen cross-link metabolites in urine as markers of bone metastases in prostatic carcinoma. J Urol. 1994;151(4):909-913.

    Not in our library10.1016/s0022-5347(17)35120-0

34. 34.

    Nakashima J., Sumitomo M., Miyajima A., Jitsukawa S., Saito S., Tachibana M., Murai M. The value of serum carboxyterminal propeptide of type 1 procollagen in predicting bone metastases in prostate cancer. J Urol. 1997;157(5):1736-1739.

    Not in our library

35. 35.

    Nguyen-Pamart M., Caty A., Feutrie M. L., Fournier C., Gosselin P., Mazeman E. The diagnostic value of urinary Crosslaps and serum alkaline phosphatase in patients with prostate cancer. Br J Urol. 1997;80(3):452-455.

    Not in our library10.1046/j.1464-410x.1997.00375.x

36. 36.

    Pecherstorfer M., Zimmer-Roth I., Schilling T., Woitge H. W., Schmidt H., Baumgartner G., Thiébaud D., Ludwig H., Seibel M. J. The diagnostic value of urinary pyridinium cross-links of collagen, serum total alkaline phosphatase, and urinary calcium excretion in neoplastic bone disease. J Clin Endocrinol Metab. 1995;80(1):97-103.

    Not in our library10.1210/jcem.80.1.7829646

37. 37.

    Pelger R. C., Hamdy N. A., Zwinderman A. H., Lycklama à Nijeholt A. A., Papapoulos S. E. Effects of the bisphosphonate olpadronate in patients with carcinoma of the prostate metastatic to the skeleton. Bone. 1998;22(4):403-408.

    Not in our library10.1016/s8756-3282(97)00289-5

38. 38.

    Pollen J. J., Witztum K. F., Ashburn W. L. The flare phenomenon on radionuclide bone scan in metastatic prostate cancer. AJR Am J Roentgenol. 1984;142(4):773-776.

    Not in our library10.2214/ajr.142.4.773

39. 39.

    Price P. A., Williamson M. K., Lothringer J. W. Origin of the vitamin K-dependent bone protein found in plasma and its clearance by kidney and bone. J Biol Chem. 1981;256(24):12760-12766.

    Not in our library

40. 40.

    Risteli J., Elomaa I., Niemi S., Novamo A., Risteli L. Radioimmunoassay for the pyridinoline cross-linked carboxy-terminal telopeptide of type I collagen: a new serum marker of bone collagen degradation. Clin Chem. 1993;39(4):635-640.

    Not in our library

Cited by papers we hold 5

• Biomarkers as therapy monitoring for postmenopausal osteoporosis: a systematic review · 2021
  No notice
• Potential of biomarkers during pharmacological therapy setting for postmenopausal osteoporosis: a systematic review · 2021
  No notice
• Use of urinary markers in cancer setting: A literature review · 2015
  Not checked
• Mechanisms of osteopontin and CD44 as metastatic principles in prostate cancer cells · 2007
  No notice
• A list of candidate cancer biomarkers for targeted proteomics. · 2007
  No notice

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.